Abstract:The objective of the present work was to study the effects of 3ø-azido-3ø-deoxythymidine (azidothymidine, Zidovudine A ) on human breast cancer cells by using, as a model, the T47D cell line (typified as oestrogen-dependent and p53-mutated). Low azidothymidine doses (3.125 mM) increase the percentage of cells in S-phase, with the effect reversing after 24 hr of incubation; as azidothymidine doses increase, the magnitude and duration of its effect increase proportionally, although, even with the highest concentrations (50-100 mM) the effects decline after 48 hr of incubation. If media (containing azidothymidine or vehicle) are daily renewed, the azidothymidine effects (accumulation of cells in S-phase) are higher and decline later than when media and drug are not changed during the whole culture period, thereby suggesting that the reversion of azidothymidine effects could be related with a degradation of the drug or accumulation in media of substances which counteract its effects. Azidothymidine inhibits T47D cell proliferation at concentrations higher than 50 mM. The exposure to 50 or 100 mM azidothymidine induced cell apoptosis after 48 hr or more of incubation. We conclude that: a) azidothymidine, with appropriate doses and duration of treatment, synchronizes cells in S-phase, inhibits proliferation, and induces apoptosis, b) the discontinuous application of the drug rather than continuous exposure to it increases its efficiency to synchronize the T47D cell cycle. This in vitro anti-breast cancer activity suggests that a possible clinical usefulness of azidothymidine, either alone or associated with other drugs with cycle-specific antitumoural activity circumscribed to the S-phase of cell cycle, is worthy of investigation.Although during recent years 3ø-azido-3ø-deoxythymidine (azidothymidine, Zidovudine A ) has been mostly used, either alone or in combination with other drugs, in the treatment of the human immunodeficiency virus (HIV) infection (Mitsuya et al. 1985), it is a drug originally synthesized as an antitumoural agent, based on its ability to block DNA synthesis. However, since its antineoplastic activity was demonstrated to be lower than that of other drugs such as 5-fluouracil, etc. (Horowitz et al. 1964), its usefulness in cancer therapy was devaluated. Recently, it has been demonstrated that azidothymidine is a potent inhibitor of MCF-7 human breast cancer cell proliferation in vitro as well as a strong in vivo inhibitor of the growth of methylnitrosourea-induced rat mammary tumors (Wagner et al. 1997). Later studies (Melana et al. 1998;Multani et al. 1998) have confirmed the antiproliferative effects of azidothymidine on breast cancer cell lines and, interestingly, that this inhibition of growth of tumoural cells is achieved with doses much lower than those required to inhibit the growth of normal breast cells. The aim of the present work was, continuing along the same lines of basic research on the effects of azidothymidine on breast cancer, to study the actions of azidothymidine at di...